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ABSTRACT 
We hypothesized that targeting key points in the ischemic cascade with combined 
neuroglobin (Ngb) overexpression and c-jun N-terminal kinase (JNK) inhibition (SP600125) 
would offer greater neuroprotection than single treatment following in vitro 
hypoxia/reoxygenation and in a randomised, blinded in vivo experimental stroke study using 
a clinically relevant rat strain.  Male spontaneously hypertensive stroke-prone rats underwent 
transient middle cerebral artery occlusion (tMCAO); groups: tMCAO; tMCAO+control GFP-
expressing canine adenovirus-2, CAVGFP; tMCAO+Ngb-expressing CAV-2, CAVNgb; 
tMCAO+SP600125; tMCAO+CAVNgb+SP600125 or sham procedure.  Rats  were assessed 
out to day 14 for neurological outcome before infarct determination.  In vitro, combined 
lentivirus-mediated Ngb overexpression+SP600125 significantly reduced oxidative stress and 
apoptosis compared to single treatment(s), following hypoxia/reoxygenation in B50 cells.  In 
vivo, infarct volume was significantly reduced by CAVNgb, SP600125 and further by 
CAVNgb+SP600125.  The number of neuroglobin positive cells in the peri-infarct cortex and 
striatum was significantly increased 14 days post-tMCAO in animals receiving CAVNgb.  
Neurological outcome, measured using a 32 point neurological score, significantly improved 
with CAVNgb+SP600125 compared to single treatments, 14 days post-tMCAO.  Combined 
Ngb overexpression with JNK inhibition reduced hypoxia/reoxygenation-induced oxidative 
stress and apoptosis in cultured neurons and reduced infarct and improved neurological 
outcome more than single therapy following in vivo experimental stroke in hypertensive rats. 
 
KEYWORDS 
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INTRODUCTION 
Currently reperfusion therapy with recombinant tissue plasminogen activator (rt-PA) is the 
cornerstone of treatment for acute ischaemic stroke, yet therapy can only be delivered to a 
fraction of patients due to a narrow therapeutic window and risk of cerebral haemorrhage 
1
.  
Extensive research has identified excitotoxicity, oxidative stress, inflammation and cell death 
(necrosis and apoptosis) as key contributory pathways underlying lesion progression 
2
.  These 
diverse injury mechanisms may explain why pharmacotherapy clinical trials geared to 
manipulate single pathways have failed.  A polytherapy approach targeting distinct pathways 
may be more effective and has shown promise in pre-clinical models 
3-4
 with the majority 
assessing the potential to extend the therapeutic window of rt-PA.  Of these, 97% used young, 
healthy animals 
3
.  The revised STAIR 
5
 and other guidelines covering pre-clinical stroke 
studies 
6
 have highlighted the need to include co-morbidities in pre-clinical stroke models to 
better model the clinical situation and improve assessment of new therapies.  The most 
significant risk factors (hypertension, abdominal obesity, diet, physical inactivity and current 
smoking) account for 80% of the global stroke risk with self-reported history of hypertension 
being the strongest of these 
7
.  This study used the spontaneously hypertensive stroke-prone 
rat (SHRSP) which displays stroke co-morbidities of hypertension, insulin resistance and 
inflammation. 
 
We chose to target two key pathways underlying stroke pathogenesis (oxidative stress and 
apoptosis) through neuroglobin upregulation in combination with JNK inhibition.  
Neuroglobin, a neuronal specific O2 binding protein, is generally considered to mediate 
neuroprotection in pre-clinical stroke studies following overexpression 
8-11
, however, it is 
worth noting that to date, neuroprotection has been demonstrated in normal rodent strains but 
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not in any strain exhibiting co-morbidity.  Administration of adeno-associated virus (AAV) 
overexpressing neuroglobin significantly reduced lesion size and improved Bederson’s 5-
point neurological score in young, normotensive rats post-MCAO 
10
.  Transgenic neuroglobin 
overexpression in mice reduced infarct volume following tMCAO 
9, 11
, however, 
sensorimotor function remained unchanged 
11
.  Intravenous delivery of neuroglobin linked to 
a fusion protein, 2 hours pre-tMCAO reduced infarct volume and neurological deficit score in 
mice 
8
.  Adenovirus, AAV and lentivirus have been used as viral vectors  to overexpress 
neuroprotective genes which has resulted in reduced infarct volume and improved functional 
outcome in permanent and tMCAO models 
12
.  Here, canine adenovirus type 2 (CAV-2 
vectors), a vector that preferentially transduces neurons and has been shown to transduce a 
greater volume of brain tissue through retrograde transport from the site of injection 
13-14
, was 
used. 
 
To provide anti-apoptotic protection we targeted JNK, a downstream mediator of extrinsic 
and intrinsic apoptosis.  A peptide inhibitor of JNK administered 6 hours post-occlusion 
reduced lesion volume and improved functional outcome following tMCAO in mice 
15
 and 
reduced infarct volume when delivered 3 hours after permanent MCAO in mice 
16
.  
Following tMCAO in spontaneously hypertensive rats, however, no such neuroprotection was 
seen 
17
.  This was attributed, in part, to the predominance of AMPA rather than NMDA 
activated ischemic brain injury in the SHR 
17
.  One further reason may be as a result of the 
greater ischemic insult achieved in SHR (or SHRSP) as the contribution of necrotic to 
apoptotic cell death may be greater and this is reflected in reduced efficacy targeting JNK 
signalling, highlighting, once again, the importance of including stroke-associated co-
morbidities in pre-clinical studies.  We used SP600125, an ATP-competitive inhibitor of 
JNK, shown previously to dose-dependently reduce infarct volume when given intravenously 
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less than 2 hours post-tMCAO in mice 
18
.  The efficacy of these agents alone has not 
previously been determined in pre-clinical stroke models displaying clinically relevant co-
morbidities and the novel combination of an anti-apoptotic and anti-oxidant represents a 
further advance. 
 
MATERIALS & METHODS 
Virus production 
As expression of the coxsackievirus and adenovirus receptor, the primary receptor for CAV-
2, was negligible on B50 rat neuronal cells used for in vitro studies (Supplementary Figure 
S1A), a neuroglobin-expressing lentivirus was generated with functional overexpression 
(mRNA and protein) confirmed (Figures 1A & 1B).  Lentiviral vectors were produced by 
triple transient transfection of HEK293T cells with a packaging plasmid (pCMVΔ8.74), a 
plasmid encoding the envelope of vesicular stomatitis virus (Plasmid Factory, Germany) and 
pHR-SIN-SFFV-Ngb, employing polyethylenimine (Sigma-Aldrich, UK) as previously 
described 
19
.  For CAVNgb production, the neuroglobin cDNA was cloned from pET3a_Ngb 
into pTCAV-12VK and recombined with pTG5412 as previously described 
20
 and propagated 
in DKZeo cells 
21
.  CAVGFP 
20
, a CAV-2 vector overexpressing green fluorescent protein as 
a reporter gene, was used as a control. 
 
Quantitative real time PCR (qRT-PCR) 
Total RNA was extracted from lysed cells 3 days post-virus transduction using the Qiagen® 
miRNeasy kit as per manufacturer’s instructions.  Qiagen® RNAse-free DNAse was added 
during the on-column phase.  RNA concentration and purity was determined by NanoDrop 
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spectrophotometry (NanoDrop Technologies, Wilmington, DE) and diluted to 200 ng/µL.  
cDNA was synthesised from 1 µg total RNA using the Taqman™ mRNA reverse 
transcription kit (Applied Biosystems, UK) with random hexamer primers.  The reactions 
underwent sequential incubation in a 96 well plate at 25 °C (10 min), 48 °C (30 min), 95 °C 
(5 min) and held at 12 °C.  Simplex reactions were performed for qRT-PCR with a specific 
neuroglobin expression probe (Rn 00583724_m1, FAM-labelled, Applied Biosystems) or 
appropriate housekeeper expression probes (GAPDH or 18S, VIC-labelled, Applied 
Biosystems).  Duplicates of each sample were incubated at 95 °C (10 min) followed by 40 
cycles of 95 °C (15 s) and 60 °C (1 min) using a Taqman™ 7900HT Fast Real-time PCR 
System (Applied Biosystems).  Samples were normalised to housekeeper and relative 
quantification (RQ) calculated from Ct (cycle threshold) vs GFP-virus treated cells.   
 
Immunocytochemistry to detect neuroglobin expression 
Neuroglobin immunocytochemistry (ICC) was performed on 4% (w/v) paraformaldehyde-
fixed cells 3 days post-virus transduction.  Briefly, cells were permeabilised in 0.1% (v/v) 
Triton / PBS for 15 min before incubation with primary antibody (10 µg/mL; 13C8, Abcam, 
UK) for 1 h at room temperature (RT).  Secondary antibody (4 μg/mL; goat anti-mouse Alexa 
Fluor 546, Invitrogen, UK; A21424) was added for 1 h at RT.  Cells were mounted using 
Prolong Gold® with DAPI (Invitrogen, UK). 
 
Hypoxia/reoxygenation (H/R) 
Rat B50 neuroblastoma cells (ECACC, UK) were maintained in Dulbecco’s minimal 
essential medium supplemented with 10% (v/v) fetal bovine serum (FBS), 2 mmol/L L-
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glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin in a 5% CO2 humidified 
atmosphere.  Cells receiving lentivirus were transduced with 5 virus particles /cell (vp/cell) 
lenti-GFP or lenti-Ngb for 4 h one day after plating.  Forty-eight hours later cells were 
switched to FBS-free medium and incubated in a hypoxic chamber (1% O2, 5% CO2, balance 
N2) for 9 h.  Ten min prior to hypoxia, cells receiving SP600125 were incubated with 20 
µmol/L or volume matched DMSO vehicle control.  Cells were reoxygenated in complete 
media, with readministration of SP600125 or DMSO where necessary, for 24 h before lysis. 
 
In vitro oxidative stress assays 
Electron paramagnetic resonance (EPR) spectroscopy for reactive oxygen species (ROS) 
detection (e-scan R; Bruker BioSpin GmbH, Germany) utilised the spin probe 1-hydroxy-3-
carboxy-2,2,5,5-tetramethylpyrrolidine (CPH; Noxygen, Germany) as previously described 
22
.  Cells were incubated in situ with Krebs buffer and 1 mmol/L CPH in a total volume of 1 
mL for 60 min at 37 °C for the last hour of the 24 h reoxygenation period.  Instrument 
settings: centre field of 3392 G, modulation amplitude of 5.08 G, sweep time of 10.49 s, 
sweep width of 120 G and 30 scans.  In the presence of ROS, CPH is oxidised to the 
nitroxide CP radical and the triple-line spectrum is read giving the EPR amplitude in 
proportion to the amount of CP• reflecting the interaction of ROS with CPH after 60 min 
giving a rate of ROS production calculated in counts per min.  All readings were normalised 
for input protein using a BCA protein assay kit (Pierce, UK). 
 
A spectrophotometric assay (Tebu-Bio, France) for malondialdehyde (MDA) was used to 
determine lipid peroxidation levels following H/R as per manufacturer’s instructions.  The 
9 
 
MDA and hydroxyalkenal determination protocol was used with 200 μl cell lysate (in PBS + 
5 μmol/L butylated hydroxytoluene, BHT).  Reaction mixtures were incubated for 60 minutes 
at 45 °C before absorbance was measured at 586nm in a spectrophotometer.  All readings 
were normalised for input protein using a BCA protein assay kit (Pierce, UK). 
 
Apoptosis assays 
Apoptosis was measured with a cell death ELISA (Roche, UK) as per manufacturer’s 
instructions.  Caspase-3 ICC was performed on 4% (w/v) paraformaldehyde-fixed cells.  
Briefly, cells were permeabilised in 0.1% (v/v) Triton / PBS for 15 min before incubation 
with primary antibody (1:30 dilution; AB32351, Abcam, UK) for 1 h at RT.  Secondary 
antibody (4 μg/mL, goat anti-rabbit Alexa Fluor 488, Invitrogen, UK; A11008) was added for 
1 h at RT.  Cells were mounted using Prolong Gold® with DAPI (Invitrogen, UK). 
 
Animals 
Animal experiments were carried out in accordance with the Animals Scientific Procedures 
Act 1986 and approved by the University of Glasgow’s Ethics Review Committee.  Male, 
SHRSP (n = 65, 270–310 g) were housed separately under a 12:12 h light:dark cycle with 
food and water ad libitum.  Studies were randomised and blinded preventing bias in selection 
and data analysis in accordance with STAIR and other guidelines 
5-6
.  For randomisation, 
treatment groups were given a number (1-6) and animals randomly allocated to a treatment 
group by a colleague not involved in performing the study using R (www.r-project.org).  
Subject groups were: sham (n=6), control tMCAO (n=9), tMCAO+CAVGFP (n=9), 
tMCAO+CAVNgb (n=9), tMCAO+SP600125 (n=9), tMCAO+CAVNgb+SP600125 (n=8).  
10 
 
The design of the in vivo intervention study is shown in Supplementary Figure S2.  
Investigators and animal unit staff caring for the animals were blinded to group allocation.  
Findings are reported in accordance with ARRIVE guidelines 
23
.   
 
Virus and drug administration 
Anaesthetic was induced with 5% isoflurane in oxygen and animals intubated and ventilated 
throughout surgery (~2.5% isoflurane/oxygen).  Body temperature was maintained at 37 ± 
0.5 °C.  Animals undergoing tMCAO had cranial burrhole surgery 5 days before tMCAO for 
virus administration or as a sham procedure.  Interestingly, this pre-stroke surgery reduces 
subsequent stroke-related mortality 
24
.  Briefly, the head was secured in a stereotactic frame, 
a 1 mm cranial burrhole made and a 24G needle connected to a Hamilton syringe used to 
pierce the dura and administer virus into the cortex.  Following a 2 min rest period 2.1 µL 
virus suspension was injected over 5 min, with a subsequent 2 min rest period before slow 
needle retraction.  A reporter gene-expressing lentivirus and CAV-2 were compared for 
transduction levels to determine which was the most efficient vector for this study.  CAV-2 
vectors (3 x 10
9
 physical particles) were injected at co-ordinates: AP + 1.2mm, ML + 3mm, 
DV – 2mm relative to bregma or 2 injections of 2 x 107 vp lentivirus injected at co-ordinates: 
AP – 0.4mm, ML + 3mm DV - 2mm and AP – 2.4mm, ML + 4mm DV - 2mm, relative to 
bregma.  For the intervention study, the site of CAV-2 injection (3 x 10
9
 physical particles) 
was AP – 0.7 mm, ML + 3mm, DV – 2mm relative to bregma.  The burrhole was then sealed 
with dental cement (Wright Cottrell).  Animals randomised to SP600125 received an 
intravenous injection [1 mg/kg in PPCES vehicle - 30% (w/v) PEG–400, 20% (v/v) 
polypropylene glycol, 15% (v/v) cremophor EL, 5% (v/v) ethanol, 30% (v/v) saline] 15 min 
pre- and 3 h post-tMCAO as previously described in mice 
18
. 
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Neurological assessments 
Each animal was trained on the neurological assessments prior to MCAO to ensure 
reproducibility at performing tasks.  Animals were assessed on a single occasion 3 days prior 
to tMCAO to ascertain a baseline score.  The 32-point neurological score used was developed 
from a series of 10 tests which assess limb function, mobility and general health, the lower 
the score the greater the neurological deficit.  Animals were further assessed by the tapered 
beam walk test, quantifying the average number of footfalls as a percentage of the total 
number taken from 3 crossings of a 130 cm tapered beam.  The animals were assessed at 
baseline 3 days prior to tMCAO and longitudinally on days 1, 2, 3, 7, 10 and 14 post-MCAO.  
Where possible, behavioural measures were completed blinded to surgery and treatment 
groups and were video recorded for assessment of footfalls and to allow for further validation 
of scores by a 2
nd
 blinded observer. 
 
Tail cuff plethysmography 
Conscious systolic blood pressure monitoring was carried out by non-invasive computerised 
tail-cuff, based on the plethysmographic method.  Rats were preheated to ~ 39 ºC for ~ 20 
minutes and restrained by wrapping in a surgical sheet, before a pneumatic pressure sensor 
was attached to the tail distal to a pneumatic pressure cuff, both under the control of a 
Programmed Electro-Sphygmomanometer.  Systolic blood pressure values from each animal 
were determined by averaging a minimum of six separate indirect pressure measurements. 
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Stroke model 
Animals were anesthetised as before and underwent tMCAO (45 min) by advancing a 
silicone-coated monofilament (Doccol Corporation, USA) through the internal carotid artery, 
blocking the origin of the MCA 
25
.  Animals were maintained under anaesthesia during the 
ischemia and then anaesthetic withdrawn and the animals allowed to recover consciousness 
after removal of the filament.  The duration of occlusion was determined to reflect a 
reproducible infarct volume and accompanying neurological deficit but with an acceptably 
low mortality rate (60 min MCAO resulted in 100% mortality in SHRSP within 2-3 days of 
experimental stroke, unpublished observation). 
 
Infarct analysis 
14 days following tMCAO rats were killed by transcardiac perfusion fixation.  Formalin-
fixed, paraffin-embedded tissue sections (6 μm) were stained with hematoxylin and eosin.  
Infarct volume was assessed at 7 coronal levels throughout the MCA territory 
26
.  Briefly, 
areas of tissue infarction were identified and the location transcribed onto scale line diagrams 
from the rat brain atlas 
27
.  Line diagrams were then scanned and infarct areas were measured 
by image analysis (Image J, NIH, USA).  The infarct volume (mm
3
) for each brain was 
calculated by plotting the area (mm
2
) of damage at each coronal level against the known 
anterior / posterior stereotaxic coordinates from Bregma and calculating the area under the 
curve.  Infarct measures were made blinded to group allocation.   
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Immunohistochemistry for virus transduction 
For determination of virus transduction efficiency and spread from the injection site, rats 
were killed by transcardiac perfusion fixation.  Brains were then placed in a 30% (w/v) 
sucrose gradient and subsequently embedded in OCT.  Frozen sections (40 µm) were 
permeabilised in 0.1% (v/v) Triton-X for 10 min and blocked for 1 h at RT.  Primary 
antibody or IgG control were diluted (1:500, GFP Abcam Ab6556; 1:500, NeuN Millipore, 
MAB377) and incubated on sections overnight at 4 °C.  Fluorescent secondary antibody [4 
µg/mL; goat anti-rabbit (GFP) or goat anti-mouse (NeuN) Alexa Fluor 488, Invitrogen, UK; 
A11008 or A11001 respectively] was incubated on the slides for 1 h at RT before mounting 
with ProLong® Gold with DAPI.  Areas of virus transduction (GFP expression) were 
identified on brain sections and their location transcribed onto scale line diagrams at 7 pre-
determined coronal levels.  The area of GFP transduction of 3 sections at each coronal level 
were delineated onto the appropriate coronal line diagrams, and measured using image 
analysis (Image J, NIH, USA). 
 
To determine levels of neuroglobin overexpression following virus delivery pre-tMCAO, 
formalin-fixed, paraffin-embedded tissue sections (6 μm) were rehydrated, endogenous 
peroxidise quenched [30 minutes in 3% (v/v) H2O2 in methanol] followed by citrate buffer 
antigen retrieval.  Sections were blocked for 1 h at RT and incubated overnight at 4 °C in 
primary antibody (1:200, Ngb, Sigma; 1:200 NeuN, Abcam) or IgG control.  Fluorescent 
secondary antibody (4 µg/mL; goat anti-mouse Alexa Fluor 546, Invitrogen, UK; A21424) 
was incubated on the slides for 1 h at RT before mounting with ProLong® Gold with DAPI.  
Images were taken on a Zeiss confocal imaging system LSM 510 (Carl Zeiss, UK) using 
settings DAPI (405) pinhole 61 µm and TRITC (546) pinhole 71 µm and objective C-
apochromat 40x/1.2W at 5 matched locations across the cortex and striatum at two coronal 
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levels [coordinates (mm): 5 sites at AP -0.12 from Bregma - ML +3.5, DV +1; ML+1, DV 
+1; ML +2, DV +4; ML +4, DV +4; ML +3.5, DV +6 and 5 sites at AP -2.28 from Bregma – 
ML +4.5, DV +1; ML +1, DV +1; ML +4, DV +4; ML +4.5, DV +6; ML 1.5, DV +4] to 
reflect the areas of high virus transduction and infarct.  To quantify the extent of neuroglobin 
expression Image Pro (Media Cybernetics, Basingstoke, UK) was used.  The area for 
quantification of neuroglobin cell count in peri-infarct tissue was selected using the Area of 
Interest Macro and pixel values were transformed to optical density units.  The number of 
cells positive for neuroglobin was then determined as a percentage of the total number of 
DAPI stained nuclei within each given field.  Image acquisition and subsequent 
quantifications were performed blinded to group allocation. 
 
Statistics 
Data are presented as mean ± s.e.m.  In vitro experiments were performed in triplicate on ≥3 
independent occasions and analysed by unpaired Students t-test.  In vivo groups were 
compared using repeated measures ANOVA.  Survival rates were compared using Fisher’s 
exact test.  Bonferroni’s or Tukey’s post-hoc test was used for multiple comparisons. 
 
RESULTS 
Neuroglobin overexpression combined with JNK inhibition protects against H/R in vitro 
B50 neuronal cells subjected to 9 h hypoxia and 24 h reoxygenation produced significant 
increases in ROS generation (Figure 2A), malondialdehyde (MDA; Figure 2B), DNA 
fragmentation (Figure 2C) and caspase-3 nuclear translocation (Figure 2D).  Lenti-Ngb pre-
treatment significantly reduced ROS generation versus controls (Figure 2A).  SP600125 
15 
 
treatment alone did not significantly reduce ROS levels but potentiated the lenti-Ngb 
mediated reduction (Figure 2A).  MDA levels appeared maximally reduced in cells pre-
treated with lenti-Ngb or SP600125.  Consequently, no further benefit of combined therapy 
was observed (Figure 2B).  Lenti-Ngb or SP600125 pre-treatment significantly reduced levels 
of apoptosis, with a further significant reduction from that seen with lenti-Ngb following 
combined intervention (Figure 2C).  In all assays those cells pretreated with the Lenti-Ngb or 
SP600125 and the appropriate control treatments (DMSO or Lenti-GFP) the same effect as 
the single active agent (either lenti-Ngb or SP600125) was found demonstrating no 
confounding effect attributable to either vehicle or virus.  Caspase-3 nuclear translocation 
was assessed qualitatively by ICC (Figure 2D).  Lenti-Ngb or SP600125 pre-treatment 
reduced the extent of nuclear translocation of caspase-3 with combined treatment returning 
the cellular distribution pattern of caspase-3 to that of normoxic cells (Figure 2D).   
 
CAV-2 vectors more efficiently transduce the adult rat cortex than lentivirus 
Different levels and distribution of reporter gene, GFP, expression were found for the 
reporter gene-expressing lentivirus and CAV-2 (Figures 3A & 3B).  One week after a single 
cortical injection of CAV-2 the rostra-caudal spread from the injection site was in excess of 7 
mm with spread through the cortical parenchyma.  In contrast, following double cortical 
injection of lentivirus spread was minimal (< 2.5 mm) from the site(s) of injection (Figures 
3A & 3B).  Determination of the tissue volume expressing the reporter gene, GFP, 
demonstrated that seen with the CAV-2 vector was significantly greater than that resulting 
from a double cortical injection of lentivirus (156 ± 11.1* vs 20 ± 3.8 mm
3
; ***p<0.0002 vs 
lentivirus Figure 3C).  Therefore, a Ngb-expressing CAV-2 virus was generated for in vivo 
studies and functional Ngb overexpression (mRNA and protein) confirmed in vitro (Figure 
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1C & 1D, respectively).  Expression of CAR mRNA, the primary receptor for CAV-2 virus, 
in the brain of SHRSP was confirmed (Supplementary Figure S1B). 
 
Neuroglobin overexpression combined with JNK inhibition protects in vivo against 
cerebral ischaemia/reperfusion 
Virus-mediated overexpression of neuroglobin 
Neuroglobin expression was determined 14 days post-tMCAO across all groups (Figure 4A), 
19 days after the CAV-2 vector was administered.  In control tMCAO animals there was a 
small, non-significant increase in the number of cells expressing neuroglobin in the peri-
infarct cortical and striatal regions (9.9 ± 1.3 %) compared to sham animals (3.1 ± 0.5 %) 
(Figure 4B).  Similarly, no significant change in the number of cells positive for neuroglobin 
expression was seen in those animals randomly allocated to receive SP600125 (5.8 ± 1.1 %) 
(Figure 4A & 4B).  The endogenous expression of neuroglobin in these groups was largely 
restricted to the peri-infarct region (Figure 4A).  In animals receiving CAVNgb alone (25 ± 
3.1 %) or in combination with SP600125 (24.6 ± 2.2 %) there was a marked and significant 
increase in the number of cells positive for neuroglobin expression within the peri-infarct 
cortex and striatum 19 days after virus administration (Figure 4A) compared to sham, control 
tMCAO or SP600125 treated animals (Figure 4B).  The increased neuroglobin expression in 
CAVNgb treated groups was evident in both cortical and striatal regions around the infarct 
(Figure 4A).  The rostro-caudal spread in enhanced neuroglobin expression following 
tMCAO appeared consistent with that seen for CAVGFP (Figure 3) with increased 
expression evident over a rostro-caudal distance of approximately 7 mm from the site of 
injection.  Neuroglobin expression was primarily co-localized with NeuN-positive cells 
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indicating a neuronal expression.  Note, not all NeuN positive cells appear positive for Ngb 
(Figure 4C). 
 
Survival and Systolic blood pressure 
No intervention affected SBP at 7 (data not shown) or 14 days post-tMCAO (Table 1).  
Furthermore, there was no significant difference in the starting/final SBP values between 
groups.  Post-tMCAO associated weight loss was similar between groups (Table 1).  Survival 
over the duration of the study was 100% in the sham (6/6) and tMCAO with combined 
intervention (8/8) groups only.  Although mortality occurred in the other groups, survival 
rates were not significantly different between groups: tMCAO 9/13; tMCAO+CAVNgb 9/10; 
tMCAO+SP600125 9/13; tMCAO+CAVGFP 9/11 (Figure 5A). 
 
Infarct volume 
Infarct volumes were comparable in untreated tMCAO control (324 ± 16.4 mm
3
, n=9) and 
tMCAO+CAVGFP (314 ± 22.2 mm
3
, n=9) rats (Figure 5B).  SP600125 and CAVNgb 
treatment (n=9 per group) significantly reduced infarct volume by 33.8% (215 ± 34.2 mm
3
*) 
and 38.6% (199 ± 14.4 mm
3
*), respectively compared to control tMCAO (*p<0.01 vs 
tMCAO).  Importantly, combined intervention (n=8) produced a greater reduction in infarct 
volume than single treatments (57%; 137 ± 20.7 mm
3*†; p<0.01 vs *tMCAO or †SP600125 
and CAVNgb).  The rostro-caudal extent of infarction in each group is shown in Figure 5C.  
Morphological analysis demonstrated that those animals receiving CAVNgb, SP600125 or 
CAVNgb+SP600125 the extent of infarct in the primary motor cortex and striatum was 
reduced vs control tMCAO or CAVGFP (Figure 5D).  However, there was a region in the 
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primary somatosensory forelimb and hindlimb cortex which was consistently infarcted 
irrespective of intervention (Figure 5D, middle panel). 
 
Neurological deficit 
All tMCAO groups exhibited a significant reduction in neurological score from baseline at 24 
hours post-tMCAO (Figure 6A).  No significant difference in neurological score was 
observed between groups over days 1-3.  At day 7, a significant improvement in neurological 
recovery was observed with combined therapy compared to control tMCAO.  However, at 
day 10 there was a significant improvement with single treatment groups compared to control 
tMCAO, but no further improvement with combination therapy.  By day 14, single treatments 
significantly improved neurological score with combined therapy producing a further 
significant improvement compared to single treatments (Figure 6A).  All tMCAO groups 
exhibited a significant increase in percentage footfalls 24 hours post-tMCAO on the tapered 
beam walk test (Figure 6B).  By day 14, a significant improvement in total footfalls was 
evident in all treatment groups versus the control group.  However, no additional 
improvement with combined therapy was observed (Figure 6B).   
 
DISCUSSION 
We describe, for the first time, an improved beneficial effect (both reduced infarct volume 
and improved neurological recovery determined longitudinally) through combined anti-
apoptotic and anti-oxidant intervention in a clinically relevant stroke model displaying 
stroke-associated co-morbidities.  Combined intervention mediated greater neuroprotection 
than either therapy alone both in vitro using a model of H/R and in vivo after tMCAO.  
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Furthermore, this study introduces neurotrophic CAV-2 vector as a platform that will allow 
better understanding of stroke pathophysiology through high levels of brain transduction.  
Together, this supports the potential for combined intervention strategies, in this case 
targeting excessive oxidative stress and apoptosis, following cerebral ischemia. 
 
In vitro studies demonstrated that neuroglobin overexpression combined with JNK inhibition 
mediated greater neuroprotection, less oxidative stress and apoptosis after H/R injury 
compared to individual treatments.  While each single treatment has been studied previously 
in neuronal cells in vitro, combination therapy has not.  Immortalised HN33 hippocampal 
neurones transfected to overexpress neuroglobin exhibited improved cell viability, measured 
by MTT assay, following 8 or 24 hours of anoxia 
28
.  Additional mechanistic studies 
determined that there was no increase in oxygen consumption in neuroglobin-overexpressing 
cells compared to controls and an involvement of nitric oxide scavenging was further ruled 
out through the failure of neuroglobin to protect against sodium nitroprusside-induced 
toxicity 
28
.  It has since been demonstrated that neuroglobin elicits protection from H/R insult 
in vitro through multiple mechanisms including improving mitochondrial function, 
maintenance of intracellular ATP levels, inhibition of calcium influx, binding to cytochrome 
c and reduced caspase 3/7 and 9 activity in human neuroblastoma cells overexpressing 
neuroglobin 
29-31
.  In the present study, vector-mediated neuroglobin overexpression resulted 
in reduced ROS generation (Figure 2).  Although neuroglobin was initially believed to act 
purely as an anti-oxidant,  studies 
29, 31
 including this study suggest anti-apoptotic effects 
through an interaction with cytochrome c, reduced caspase 3/7 or 9 activity/nuclear 
localisation and DNA fragmentation (reviewed in 
32
).  It is impossible to distinguish 
unequivocally between apoptotic and oxidative stress pathways as they are inextricably 
linked with extensive crosstalk between.  However, neuroglobin directly activates the 
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PI3K/AKT/mTOR pathway of cell survival 
33
.  Furthermore, JNK may be involved in pro-
oxidant pathways since the N-terminal Von Hippel-Lindau recognition site of hypoxia 
inducible factor-1α contains a JNK binding domain 34. 
 
Notably, translation to an in vivo stroke model confirmed that combined neuroglobin 
upregulation and JNK inhibition was better than single treatment using infarct size and 
neurological deficit as outcome measures (Figures 4-6).  The greatest reduction in infarct 
size, detected in the combination treatment group, was accompanied by an improved 
neurological score and reduction in footfalls at day 14.  The tapered beam walk test failed to 
demonstrate any additional improvement with combined treatment which likely reflects the 
conserved region of infarct within the primary somatosensory forelimb/hindlimb cortex in all 
groups (Figure 5D).  There was a trend towards an increase in endogenous neuroglobin levels 
14 days following tMCAO in the SHRSP although this was not significantly enhanced 
compared to sham (Figure 4).  We cannot exclude the possibility that peak neuroglobin levels 
occurred earlier and returned toward basal levels 2 weeks after cerebral ischemia.  
Endogenous upregulation of neuroglobin in cells in the peri-infarct region agrees with other 
preclinical 
28
 and clinical stroke studies 
35
 where increased neuroglobin levels were reported.  
Importantly, virus-mediated overexpression of neuroglobin was sustained to 14 days after 
tMCAO (19 days post-administration) in those animals randomised to receive CAVNgb or 
the combined treatment.  Interestingly, in SP600125 treated animals, which had a similar 
infarct volume to the CAVNgb single intervention group, there was no difference in the 
number of neuroglobin positive cells compared to sham.  This may reflect that with the 
smaller infarct resulting from SP600125 treatment, the stimulus for endogenous neuroglobin 
upregulation following tMCAO was reduced.  Interestingly, in the intervention study, 
increased neuroglobin expression was detected in the striatum and cortex following virus 
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delivery and tMCAO.  Striatal gene expression was not evident from the CAVGFP 
administration in naive rats (Figure 3).  While we cannot distinguish between endogenous or 
virus-mediated upregulation in neuroglobin expression within the striatum, we can postulate 
that following tMCAO transduction profiles may differ or that there is an active transport 
process occurring similar to what has previously been described with CAV-2 vectors 
36
. 
 
Previous studies determining the neuroprotective effect of neuroglobin in vivo demonstrated 
neuroglobin overexpressing transgenic mice had lower levels of lipid peroxidation measured 
by MDA assay in the ipsilateral hemisphere following tMCAO 
11
.  In addition, reduced 
numbers of TUNEL-positive cells and increased numbers of neurones with a normal 
morphology (from cresyl violet histology) were seen following delivery of neuroglobin 
linked to a fusion protein prior to tMCAO in C57BL/6J mice 
8
.  The current study 
demonstrates that in spite of the multifaceted mechanism of action of Ngb (anti-oxidant and 
anti-apoptotic) that further protection can be afforded through combined JNK inhibition.  All 
previous experimental stroke reports of neuroprotection afforded by neuroglobin have been 
determined in normal mice or rats or using transgenic overexpression 
8-11
.  In using SHRSP, 
which exhibit a number of stroke-related co-morbidities, we have addressed STAIR 
guidelines 
5
 as hypertension was reported as the strongest risk factor for stroke in a global 
case-study 
7
.  Furthermore, all analyses were performed under blinded conditions with 
animals randomly assigned to experimental groups and blood pressure monitoring 
throughout, in accordance with the pre-clinical stroke study guidelines 
6
.  Of 142 publications 
describing combined therapy for stroke only 3% have used hypertensive rats 
3
.  The majority 
of these determined the potential for adjuvant therapy to extend the therapeutic window for 
rt-PA 
4
.  Only one combination treatment study (anti-oxidant tempol and/or 
cannabinoid/NMDA antagonist dexanabinol following permanent MCAO) used hypertensive 
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rats and this failed to identify any additional benefit of combined treatment, attributing this to 
a ceiling neuroprotection achieved by either single treatment 
37
.  We designed our study to 
limit this possibility.  The dose of SP600125 used (1 mg/kg) was selected based on previous 
studies in mice demonstrating a significant, but sub-maximal (seen at 3 mg/kg), reduction in 
infarct volume after tMCAO 
18
 in an attempt to avoid a similar ceiling effect.  A recovery 
period of 14 days was set to ensure capture of final infarct size (shown previously to continue 
to evolve 48-72 hours post-tMCAO in rats 
38
) and allow serial assessment of neurological 
outcome measures.   
 
The utility of CAV-2 vectors for neurodegenerative diseases has previously been 
demonstrated in dopamine-deficient mice where CAV-2 transduced neurons expressed 
tyrosine hydroxylase for >1 year from delivery 
39
.  More recently in a lysosomal storage 
disorder, neonatal delivery led to persistant transgene expression and normalization of the 
functional deficit for up to 20 weeks 
40
.  A single cortical CAV-2 injection efficiently 
transduced neurons and resulted in an 8-fold greater transduction volume and covered a 
greater rostral-caudal distance than lentivirus in the present study.  In this, the first study 
using CAV-2 in a cerebral ischemia model, increased levels of neuroglobin transduction 
remained in neurons of peri-infarct cortical and striatal regions 2 weeks after tMCAO and 19 
days post-CAV delivery, demonstrating sustained and selective transgene expression.  Gene 
and cell based-therapies are now being clinically tested for a wide range of diverse disease 
pathologies.  While the success of the CAV-2 vector to directly deliver neuroglobin to the 
brain parenchyma overcomes limitations relating to the ability of pharmacological anti-
oxidants to reach the brain by failure to cross the blood-brain barrier, translation of novel 
gene delivery vectors, such as CAV-2, will require further extensive pre-clinical research.  A 
more feasible clinical prospect may be through pharmacological upregulation of neuroglobin 
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to similar levels achieved with CAV-2 vectors.  A recent study described the use of the prolyl 
hydroxylase inhibitor (PHI) deferoxamine and the short-chain fatty acids cinnamic and 
valproic acids to pharmacologically increase neuroglobin expression in HN33 cells in vitro 
41
.  
However, whether such an effect on neuroglobin expression is also evident in vivo has yet to 
be described.  In addition, these agents are likely to affect a number of pathways in addition 
to merely upregulating neuroglobin – the PHIs, for example, enhance levels of hypoxia 
inducible factor-1 and -2 resulting in neuroprotection through a plethora of target 
pathways 
42
. 
 
In conclusion, the combination of anti-apoptotic JNK inhibition and anti-oxidant neuroglobin 
upregulation demonstrates a significant neuroprotective potential when administered prior to 
tMCAO.  This study demonstrates that targeting these pathways in combination improves 
efficacy compared to a single target using an animal model exhibiting stroke-associated co-
morbidities.  Further use of such a combined approach targeting excessive oxidative stress 
and apoptosis may be applicable in disease settings where these pathways are implicated, 
such as neurodegenerative disorders (Alzheimer’s disease, Parkinson’s disease), traumatic 
brain injury or hypoxic insult (such as hypoxic-ischemic neonatal encephalopathy, a problem 
in perinatal medicine).  The next step in stroke translation will be to assess if neuroprotection 
and improved outcome can be achieved when treatment is delivered in the acute post-stroke 
period and if it can act additively or synergistically with thrombolysis.  However, although 
many single and combination therapeutic approaches have proven successful in pre-clinical 
models, this has not led to successful translation in stroke patients and thrombolysis within a 
tight time frame of the onset of acute cerebral ischemia remains the primary intervention at 
this time.   
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Figure 1: Confirmation of neuroglobin-overexpression from viral vectors.  Functional 
overexpression of Ngb was assessed by TaqMan™ qRT-PCR (mRNA) and ICC (protein) in 
B50 neuronal (lenti-Ngb) or HepG2 (CAVNgb) cells 3 days post-transduction.  (A, C) Ngb 
mRNA levels were normalised to GAPDH (B50 cells, lenti-Ngb) or 18S (HepG2 cells, 
CAVNgb) following viral transduction.  Relative quantification (RQ) was calculated from 
∆∆Ct (cycle threshold) and compared to GFP-expressing virus levels.  RQ ± RQmax/RQmin 
shown and analysed by Student’s unpaired t-test with Bonferroni’s post-hoc correction.  
*p<0.01 and **p<0.001 vs GFP-expressing virus, n=3.  (B, D) Representative 
photomicrographs of Ngb protein expression determined by ICC in cells transduced with 
Ngb-expressing viruses using an -Ngb antibody (B: nuclei=blue, DAPI; both: Ngb=red, 
TRITC).  Negative staining in isotype-matched IgG controls shown for lenti-Ngb, untreated 
cells represent basal expression levels of neuroglobin expression.  Scale bar = 100 µm. 
 
Figure 2:  Neuroglobin overexpression combined with JNK inhibition protects against 
H/R injury in vitro.  Normoxic control cells (solid bars) received the same treatment as cells 
exposed to 9 hours hypoxia with 24 hours reoxygenation (hypoxic; open bars).  Oxidative 
stress assays for H/R injury: (A) ROS generation detected by EPR; (B) lipid peroxidation 
levels by MDA assay and apoptosis by: (C) Apoptotic cell death ELISA and (D) caspase-3 
(green) ICC (nuclei=blue, DAPI).  Scale bar, 100 µm.  Data presented as mean±s.e.m., 
analysed using unpaired Student’s t-test and Bonferroni’s post-hoc correction, representative 
of n=3.  *p<0.01 vs untreated hypoxic cells, †p<0.001 vs. lenti-Ngb or SP600125 treated 
hypoxic cells, #p<0.01 vs. lenti-Ngb treated hypoxic cells. 
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Figure 3:  Comparative transduction levels from CAV-2 and lentivirus in adult rat 
brain.  (A) Rostro-caudal gene transduction (grey) following single injection of 3 x 10
9
 vp 
CAVGFP (n=4; left) and double injection of 2 x 10
7
 vp lenti-GFP (n=4; right) determined 
from the median animal in each virus group.  Black dots represent cortical injection sites.  
The staining pattern of GFP expression was transcribed onto stereotaxic atlas plates 
27
.  (B) 
Representative cortical images of GFP epifluorescence from lentivirus or CAV-2 
transduction 7 days after stereotactic injection; scale bar, 100 µm (top) and 20 µm (bottom).  
Images taken from the primary somatosensory cortex (S1FL) at coronal level Bregma -
0.12mm (indicated with an X on atlas plate image).  (C) Volume of tissue transduced by each 
viral vector quantified from area under the curve analysis across 7 coronal levels.  Data 
presented as mean±s.e.m.; ***p<0.0002 vs lentivirus using Student’s unpaired t-test. 
 
Figure 4:  CAV-mediated overexpression of neuroglobin following stereotactic delivery 
and subsequent tMCAO.  (A) Infarct location (grey) and representative distribution of 
neuroglobin expression (red) for each group (top panel) determined by IHC 19 days after 
CAV delivery and 14 days post-tMCAO.  Representative images showing levels of 
neuroglobin expression at 2 distinct peri-infarct sites (Bregma -0.12mm, cortical site, top 
panel or Bregma -2.28mm, striatal site, bottom panel) following tMCAO.  Inset panels 
representative of isotype matched IgG control staining.  Scale bar, 50 µm.  Image location 
indicated by X on atlas plate - primary somatosensory cortex (S1FL) or striatum (Str).  (B) 
Quantification of neuroglobin positive cells expressed as a percentage of total cells (DAPI 
nuclear stain) within 5 matched locations across the cortex and striatum at 2 coronal levels.  
Data presented as mean±s.e.m. and analysed by ANOVA using Tukey’s post-hoc correction.  
**p<0.001 vs sham, †p<0.01 vs. control tMCAO and ##p<0.001 vs. tMCAO+SP600125.  (C) 
Representative double labelled images of immunopositive neurones (NeuN) and neuroglobin-
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positive (Ngb) cells at coronal level Bregma -2.28mm in the striatum (Str).  Representative 
dual labelled cells indicated by arrows.  Scale bar, 50 µm. 
 
Figure 5:  Neuroglobin overexpression combined with JNK inhibition does not affect 
mortality but reduces infarct volume following ischemia/reperfusion in vivo.  (A) 
Kaplan-Meier curves showing comparable survival rates between sham, tMCAO and 
intervention groups using Fisher’s exact test.  (B) Infarct volume determined 14 days post-
tMCAO.  Individual data points for each animal, with line representing the mean.  (C) 
Rostro-caudal distribution of infarct.  Data presented as mean±s.e.m. and analysed by one 
way ANOVA with Bonferroni’s post-hoc correction; p<0.01 vs *tMCAO, 
†tMCAO+SP600125 or tMCAO+CAVNgb and #tMCAO+SP600125.  (D) Representative 
transcribed infarct (top panel) and H&E images (middle and bottom panels) from the median 
animal in each group at coronal level Bregma -0.12mm.  Middle panel - primary 
somatosensory cortex (S1HL & S1FL, indicated with 1 on atlas plate image) and bottom 
panel – striatum (Str, indicated with 2 on atlas plate image).  Scale bar, 50 µm. 
 
Figure 6:  Neuroglobin overexpression combined with JNK inhibition improves 
neurological deficit.  (A) 32-point neurological score measured general condition, righting 
reflex, grip strength, paw placement, circling, horizontal bar, inclined platform, visual 
forepaw reaching, rotation and mobility.  (B) Movement on tapered beam was tracked, 
footfalls onto an under-hanging ledge recorded for both ipsi- and contralateral side and 
expressed as a percentage of footsteps taken.  Data presented as mean±s.e.m. and analysed by 
ANOVA using Bonferroni’s post-hoc correction, (n=6-9 per group).  *p<0.01 vs. tMCAO 
and †p<0.01 vs. single treatment. 
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Table 1:  Physiological parameters.  SBP measured 3 days pre- (baseline), 7 days and 14 
days post-tMCAO (pre-sacrifice) and the change in body weight over the corresponding 
period.  Data presented as mean±s.e.m, n=6-9. 
